Literature DB >> 8221668

Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications.

D F Jelinek1, G J Ahmann, P R Greipp, S M Jalal, J J Westendorf, J A Katzmann, R A Kyle, J A Lust.   

Abstract

A new human myeloma cell line, ANBL-6, was established and characterized at the genotypic and phenotypic levels. The cells exhibit a clonally rearranged immunoglobulin gene locus and resemble plasma cells morphologically. The ANBL-6 cells also exhibited an absolute dependence on exogenous interleukin 6 for growth. Of interest, DNA ploidy analysis suggested the existence of a near-diploid as well as a near-tetraploid population in this cell line. Cytogenetic studies confirmed the existence of two aneuploid karyotypes and further revealed a clonal relationship between the two karyotypes, as evidenced by numerous shared structural abnormalities. To determine whether the near-diploid cells functioned as stem cells for the near-tetraploid population, the near-diploid population was separated via flow cytometry and recultured prior to ploidy analysis. This population was observed to remain predominantly near-diploid over time, suggesting that these cells did not function as stem cells for the near-tetraploid population. However, the near-tetraploid cells did exhibit a growth advantage in vitro. Moreover, sequential ploidy analysis performed retrospectively on fresh bone marrow cells from the patient also suggested that there was an expansion of the near-tetraploid population during clinical relapse. These results suggest that both populations are self-regenerating and reflect the consequences of clonal evolution in the myeloma tumor. The coexistence of clonally related subclones with shared chromosomal abnormalities, however, suggests that the near-tetraploid subclone was derived from the near-diploid subclone at an unknown time during tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221668

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.

Authors:  Alexandra J Greenberg; Denise K Walters; Shaji K Kumar; S Vincent Rajkumar; Diane F Jelinek
Journal:  Eur J Haematol       Date:  2013-09-17       Impact factor: 2.997

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.

Authors:  Denise K Walters; Bonnie K Arendt; Diane F Jelinek
Journal:  Cell Cycle       Date:  2013-09-03       Impact factor: 4.534

4.  Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Authors:  D K Walters; X Wu; R C Tschumper; B K Arendt; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

5.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

6.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

7.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

8.  Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Exp Hematol       Date:  2015-08-06       Impact factor: 3.084

9.  Infection and killing of multiple myeloma by adenoviruses.

Authors:  Julien S Senac; Konstantin Doronin; Stephen J Russell; Diane F Jelinek; Philip R Greipp; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-02       Impact factor: 5.695

10.  Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma.

Authors:  Nancy D Borson; Martha Q Lacy; Peter J Wettstein
Journal:  Mamm Genome       Date:  2006-03-03       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.